Tolterodine ( DrugBank: Tolterodine )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
17多系統萎縮症1
53シェーグレン症候群1

17. 多系統萎縮症


臨床試験数 : 118 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100046394
2021-06-012021-05-15Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy multiple system atrophyExperimental group:Drug (tolterodine) combined with electrical stimulation;Xuanwu Hospital, Capital Medical UniversityNULLRecruiting3075BothExperimental group:50;N/AChina

53. シェーグレン症候群


臨床試験数 : 283 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04909255
(ClinicalTrials.gov)
March 23, 202121/4/2021Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive BladderThe Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome PatientSjogren's Syndrome;Overactive Bladder SyndromeDrug: mirabegron;Drug: oxybutynin, tolterodine, solifenacinChina Medical University HospitalNULLRecruiting20 YearsN/AAll50Phase 4Taiwan